Drug Profile
BLX 1002
Alternative Names: BLX-1002Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator BEXEL Pharmaceuticals
- Class Amino acids; Anti-inflammatories; Small molecules
- Mechanism of Action Interleukin 6 inhibitors; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Type 2 diabetes mellitus; Unspecified
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Undefined in USA
- 24 Nov 2010 No development reported - Phase-II for Type-2 diabetes mellitus in Europe (PO)
- 11 Sep 2008 Pharmacodynamics data from a preclinical trial Diabetes mellitus presented at the 44th Annual Meeting of the European Association for the Study of Diabetes (EASD-2008)